Preventing the Emergence of Antimicrobial Resistance (AMR) in STIs
A special issue of Antibiotics (ISSN 2079-6382).
Deadline for manuscript submissions: closed (31 December 2021) | Viewed by 8903
Special Issue Editor
Special Issue Information
Dear Colleagues,
The prevalence of antimicrobial resistance (AMR) in bacterial STIs is increasing in many populations around the world. Concerns have been raised that Neisseria gonorrhoeae and Mycoplasma genitalium may be untreatable in the not-too-distant future. AMR in Neisseria gonorrhoeae, Mycoplasma genitalium, and Treponema pallidum is not, however, inevitable. N. gonorrhoeae isolates from parts of Australia, for example, remain susceptible to almost all classes of antibiotics, which means that penicillin can still be used as first-line therapy. Differences in antimicrobial consumption (AMC) play a key role in determining the large differences in the prevalence of AMR. Whilst AMC in the population at large plays a role, excessive AMC in core-groups is crucial. There is an urgent need to better characterize the relationship between AMC (in the general population and core-groups) and AMR in STIs. Furthermore, research is required into how to reduce AMC in these populations as well as developing alternatives to antimicrobial therapy—such as mouthwashes, bacteriophage therapy or vaccines. This Special Issue seeks manuscript submissions that advance our understanding of how best to prevent the emergence and spread of AMR in bacterial STIs. Submissions dealing with any aspect of the prevention of resistance in bacterial STIs are welcome.
Prof. Christopher Kenyon
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibiotics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- AMR
- STI
- Prevention
- Antibiotic stewardship
- Antimicrobial resistance
- Neisseria gonorrhoeae
- Mycoplasma genitalium
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
